Saudi Journal of Gastroenterology

ARTICLES
Year
: 2004  |  Volume : 10  |  Issue : 1  |  Page : 22--27

Ulcerative colitis: Al-gassim experience


Qais Qutub Contractor1, Tasneern Qais Contractor2, Imran Ul Haque3, El Mahdi El Badawi El Mahdi1,  
1 Department of Medicine, King Fahad Specialist Hospital, Buraidah, Al-Gassim, Saudi Arabia
2 Department of Surgery, King Fahad Specialist Hospital, Buraidah, Al-Gassim, Saudi Arabia
3 Department of Laboratory Medicine, King Fahad Specialist Hospital, Buraidah, Al-Gassim, Saudi Arabia

Correspondence Address:
Qais Qutub Contractor
King Fahad Specialist Hospital, P 0 Box 2290, Buraidah, Al-Gassim
Saudi Arabia

Abstract

Background: Ulcerative colitis (UC) is being reported more frequently among the Arabs. Information on the clinical severity, endoscopic and histological grading is scanty. Aim: To assess the severity of the disease and its response to therapy in patients referred to a tertiary care referral centre in Gassim region, Kingdom of Saudi Arabia (KSA). Patients and Method: Hospital records of thirty-four patients found to have UC from 1990-2002 were analyzed. The study included clinical severity, endoscopical and histological assessment, response to therapy and frequency of complications. Results: There were 21 males and 13 females with median age 35 (range: 18-76) years. The disease was clinically mild in seven patients (21%), moderate in 11 (32%) and severe in 16 (47%). Endoscopically UC was graded as 2 in three patients (9%), 3 in 21 patients (59%) and 4 in ten patients (29%). Histologically UC was mild to moderate in 11 patients (32%) and severe in 23 (68%). Extent of UC was total in nine patients (26%), up to transverse colon in six (18%), splenic flexure in 14 (41%), rectosigmoid region in four (12%) and only up to the rectum in one (3%). Twenty-nine patients (85%) were treated with salazopyrine and five patients (15%); (two of them were hypersensitive to salazopyrine) received 5­aminosalicylic acid. Proctocolectomy was performed in two with a focus of malignancy. No patient died during the median follow-up period of 48 months (range: 4 months to 12 years). Conclusion: Ulcerative colitis presented with varying severity, more frequently in males in the population studied. Most of the patients responded to salazopyrine and surgery was necessary when malignancy was detected



How to cite this article:
Contractor QQ, Contractor TQ, Ul Haque I, El Mahdi EE. Ulcerative colitis: Al-gassim experience.Saudi J Gastroenterol 2004;10:22-27


How to cite this URL:
Contractor QQ, Contractor TQ, Ul Haque I, El Mahdi EE. Ulcerative colitis: Al-gassim experience. Saudi J Gastroenterol [serial online] 2004 [cited 2023 Feb 2 ];10:22-27
Available from: https://www.saudijgastro.com/text.asp?2004/10/1/22/33348


Full Text

Two decades ago Kirsner and Shorter made an observation that inflammatory bowel disease is rare or non-existent in Saudi Arabia [1] . Few reports were published thereafter stressing that ulcerative colitis did exist in the Arab world [2],[3],[4] . Ulcerative colitis is now being reported from both the urban and rural areas of the KSA [5],[6] . Since environmental factors have been implicated in its etiology, the rapidly changing lifestyle in these countries could be a possible cause for the rising incidence of inflammatory bowel disease in this part of the world [7] . Although the incidence rate of UC in KSA is not known, it is possibly low as it belongs to the low-incidence areas, where the incidence is approximately ten-fold less than in the high-incidence areas. Annual frequency of newly diagnosed cases among patients evaluated by lower gastrointestinal endoscopy has varied from 0.01 % to 6% in earlier reports from KSA [4],[8] . These figures are similar to ones in Kuwait and Iran [2],[9]. It is now well recognized that UC is a worldwide disorder and the diagnosis may be difficult, where infective colitis is common since the endoscopic findings are similar. Improving health care facilities has also resulted in better recognition of this disease in KSA.

Reports from a few regions of KSA have described the disease in these areas and compared it to that in the high-incidence areas [5],[6]. We have analyzed and categorized the clinical presentation, endoscopic and histological staging of the disease and its response to therapy in patients referred to our centre in Gassim region.

 Patients and Methods



Over a 12-year period (December 1990­December 2002), 34 patients were diagnosed to have UC on the basis of clinical features, endoscopic findings, histological characteristics and after excluding commonly occurring infections such as amebiasis, shigellosis, salmonellosis as well as tuberculosis and schistosomiasis. Clinical severity was classified according to the criteria of Truelove and Witts [10] . Sigmoidoscopic findings were conveniently graded from 0-4 as has been recommended [7] . Histologic assessment of inflammation was graded as: non-significant, mild to moderate and severe [11] .

Complete hemogram, ESR, stool microscopic examination and culture, complete serum chemistry, and C-reactive protein (CRP) were requested at the time of presentation. Colonoscopic examination was recommended for all patients after sigmoidoscopic assessment. Those who did not consent to it had an air double contrast barium enema. Patients with moderate and severe UC received prednisone 30-40mg daily that was reduced over 2-3 weeks as the patient went into symptomatic, endoscopic and histologic remission. If required, the dose of prednisone was increased to induce remission. Salazopyrine was gradually increased to at least 2gms/day to maintain endoscopic and histologic remission. Those who were hypersensitive to salazopyrine were put on 5-amino salicylle acid (enteric coated mesalazine) 800mg daily and the dose was increased to maintain endoscopic and histological remission.

Follow-up endoscopic and histologic assessment was done every six months or if the patient had a symptomatic relapse. Endoscopic documentation of mucosal status is a useful objective indication of the response to treatment [12] . If an endoscopic and histologic remission was maintained. attempt was made to reduce the dose of the medication the patient was receiving. If the patient remained in remission on salazopyrine lgm/day or mesalazine 800mg/day for three years period, then treatment was discontinued and patient was followed up. If symptoms recurred or follow-up endoscopy showed recurrence of the disease, medications were again started. Ten years after the onset of the disease patients underwent surveillance colonoscopy every year. If malignancy or high grade dysplasia were detected, proctocolectomy was advised. If low grade dysplasia was detected, then a repeat colonoscopy would be performed after one­month and if it was confirmed, surgery would be advised [7] .

 Results



Clinical characteristics of the patients at the time of presentation are shown in [Table 1] .Out of the 34 patients 32 were Arabs and two were non-Arab Asians. None of the patients were smokers, no other family member was affected and no patient had an appendectomy in the past. Arthritis of right knee and right hip were diagnosed in two patients. One patient was detected to have right frontal meningioma, which was operated. One is receiving L-thyroxine for hypothyroidism and one had laparoscopic cholecystectomy for cholelithiasis. There were RBCs and pus cells in the stool on microscopic examination in all the patients and stool cultures were negative. Serum albumin was [13] . Most of the familial association are in first degree relatives and affected members may have either UC or Crohn's disease. Familial association was not noted in any of our patients. It is generally reported that women are more commonly affected than men but several studies have failed to find this sex difference [14],[15] . Previous reports from KSA have attributed the male predominance to the under reporting of rectal problems by females in this part of the world. Men were more frequently affected in the present study, considering the previous reports this difference is likely to be real.

None of our patients were smokers and this could be due to the fact that smoking is socially and culturally discouraged in this region of KSA. Appendectomy was not performed in any of our patients. Although nonsmoking and low appendectomy rates have been implicated in the etiology of UC, the present number of patients is too small to draw any conclusions [16],[17] . An association between emotional factors and UC and its role as an etiological factor has been noted for a long time [18] . The significance of life events stress in UC was strongly substantiated at all levels in a case control study from the Eastern Province from KSA [19] . None of our patients had a psychiatric assessment but clinically there was no obvious mental state dysfunction.

Extraintestinal manifestations are reported to be uncommon among Saudis [5],[6] . Only two of our patients had arthritis, involving the hip and knee, and this finding is in keeping with previous observations. An acute arthropathy affecting the larger joints in an asymmetric fashion is known to occur in 10% to 15% of the patients [7] . It resolves as the colitis goes into remission. At presentation, about half the patients had clinically severe UC and the majority had severe inflammation on histology and grade 3 or 4 UC on sigmoidoscopy. Twenty-four patients received oral steroids for inducing remission. Ten patients with distal colitis received hydrocortisone retention enema. The classic controlled trial of cortisone acetate by Truelove and Witts has firmly established the beneficial role of glucocorticoids in treating active UC [10] . Comparison between three different doses of prednisone has shown that response is optimum to 40mg as compared to 20mg [7] . Given as a retention enema, betamethasone 17-valerate, beclomethasone and prednisolone metasulfobenzoate are therapeutically effective for distal colitis with minimal effects on the hypothalamic­ pituitary-adrenal axis [20] . Budesonide is also effective both as a retention enema and a colonic-release preparation.

On 2-3gm of salazopyrine daily, most of the patients could be kept in remission. Serial sigmoidoscopie and histological assessment has been recommended in clinical practice to assess the response to therapy [12] . Although the dose of salazopyrine could be reduced to I gm in five patients and 1.5gm in three and three of these could be kept off therapy for six months to two years, all the patients eventually needed medications. None of the patients following up with us needed immunosuppressants. It seems from our experience that UC responds well to therapy in this part of the world and remission can be maintained in some patients on much lesser medication than that required in high-incidence areas [21] .

Sulphasalazine is usually well tolerated but 30% are believed to report adverse reactions [22] . In the present study only two patients could not tolerate this agent due to hypersensitivity and had to be put on mesalazine. The dose-dependent adverse effects were overcome by starting the dose at 0.5gm daily and gradually increasing it over a week. Five patients were eventually treated with enterically coated mesalazine. Adverse effects with these drugs occur in less than 5% of patients. There are several mesalazine preparations as well as two prodrugs, olsalazine and balasalazide. It is not very clear, which of these compounds should be preferred. Topical treatment with these drugs is also effective in treating active distal colitis [23] . The most widely used immunosuppressants are azathioprine and 6-mercaptopurine. Intravenous cyclosporine is being increasingly used in severe UC. Anecdotal evidence suggests that weekly administration of methotrexate is effective for patients with refractory disease [7] . Extent of involvement in the present study is similar to that reported in the past from KSA. Surgical intervention for high grade dysplasia and adenocarcinoma in the transverse colon was necessary for two of our patients. Hence the risk of cancer should not be underestimated in this part of the world [6] .

In conclusion, UC in Gassim Region presents with varying severity but response to therapy is good. Remission can be maintained in some patients with a small dose of salazopyrine and few can go off the medications for six months to two years. There is a definite risk of malignancy and cancer surveillance after ten years of the illness is mandatory.

References

1Kirsner JB, Shorter RG. Recent development in inflammatory bowel disease. N Engl J Med 1982; 306: 837-48.
2Al-Nakib B, Radhakrishan S, Jacob GS, et al. Inflammatory Bowel Disease in Kuwait. Am J Gastroenterol 1984; 79: 191-4.
3Mohammed AE, Al-Karawi M, Hamid MA, Yassawy 1. Lower Gastrointestinal tract pathology in Saudis: Results of endoscopic biopsy findings in 1600 patients. Ann Saudi Med 1987; 7: 306-11.
4Hossain J, Al-Faleh FZ, Al-Mofleh 1. Al Aska AK, Laajam M, Al Rashid R. Does ulcerative colitis exist in Saudi Arabia? Analysis of thirty­seven cases. Saudi Med J 1989; 10: 360-2.
5Khan HA. Mahrous AS. Khawaja Fl. Ulcerative colitis among the Saudis: Six year experience from Al-Madinah region. Saudi J Gastroenterol 1996; 2: 69-73.
6Alamin AHK, Ayoola EA, El Boshra ASI, Hamaza MK, Gupta V, Ahmed MA. Ulcerative colitis in Saudi Arabia: A Retrospective analysis of 33 cases treatedin a regional referral hospital in Gizan. Saudi J Gastroenterol 2001; 7: 55-8.
7Jewell DP. Ulcerative Colitis. In: Feldman M, Friedman LS, Sleisenger MH. (Eds). Sleisenger Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. Seventh edition. Philadelphia: Saunders, 2002: 2039-67.
8Satti MB, Al-Qurain A, Al-Gindan YM. Al­Hamdan A. Chronic idiopathic ulcerative colitis in Saudi Arabia. A clinicopathological study of 76 cases. Ann Saudi Med 1996; 16: 637-40.
9Melgiessi SH, Furouzandeh B, Gadimi R. Ulcerative colitis in Iran: A review of 112 cases. Am J Gastroenterol 1985; 80: 863-6.
10Truelove SC, Witts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. BMJ 1956;2:1041.
11Truelove SC, Richards WRD. Biopsy studies in Icerative colitis. BMJ 1956; 1: 1315.
12Hanauer SB. Medical Therapy in Ulcerative Colitis. In: Kirsner JB, Shorter RG, (Eds). Inflammatory Bowel Disease. Fourth edition. Philadelphia: Williams & Wilkins, 1995: 665.
13Satsangi J. Jewell DP, Rosenberg WMC, Bell JI. Genetics of inflammatory bowel disease. Gut 1994; 35: 696-700.
14Mendeloff Al. Epidemiologic aspects of inflammatory bowel disease: Berk JE, (Ed). Bockus Gastroenterology Volume 4, fourth edition. Philadelphia: Saunders 1985: 2127-36.
15Van Gossum A, Adler M, De Reuck M, et al. Epidemiology of inflammatory bowel disease in Brussels' area (1992-1993). Acta Gastroenetrol Belg 1996; 59: 7-9.
16Lindberg E, Tysk C, Anderson K, Jarnerot G. Smoking, and inflammatory bowel disease. A case control study. Gut 1988; 29: 352-8.
17Rutgeerts P. Dhaens G, Hiele M, et al. Appendectomy protects against ulcerative colitis. Gastroenterology 1994; 106: 1251-3.
18Murray CD. Psychological Factors in Etiology of Ulcerative Colitis and Bloody Diarrhea. Am J Med Sci 1930; 180: 39-48.
19Abumadini MS. Hafeiz HB. Al-Qurain A, Yassawy M1, Abdulkarim MM. Life events stress in ulcerative colitis: A case control study. Saudi J Gastroenterol 2002; 8: 53-8.
20Jewell DP. Corticosteroids for the management of ulcerative colitis and Crohn disease. Gastroenterol Clin North Am 1989; 18: 21-34.
21Azad Khan AK, Howes DT. Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in lcerative colitis. Gut 1980;21: 232-40.
22Taffet SL, Das KM. Sulfasalazine: Adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-42.
23Campieri M, Gionchetti P, Belluzzi A. Optimum dosage of 5-aminosalicylie acid as rectal enema in patients with ulcerative colitis. Gut 1991; 32: 929-31.